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Myelosuppression is the major dose-limiting toxicity of cancer chemotherapy. There have
been many attempts to find new strategies that reduce myelosuppression. The dietary
supplementation with lactic acid bacteria (LAB) improved respiratory innate immune
response and the resistance against respiratory pathogens in immunosupressed hosts.
Although LAB viability is an important factor in achieving optimal protective effects, non-
viable LAB are capable of stimulating immunity. In this work, we studied the ability of oral
preventive administration of viable and non-viable Lactobacillus rhamnosus CRL1505 or
L. plantarum CRL1506 (Lr05, Lr05NV, Lp06V or Lp06NV, respectively) to minimize
myelosuppressive and immunosuppressive effects derived from chemotherapy.
Cyclophosphamide (Cy) impaired steady-state myelopoiesis in lactobacilli-treated and
untreated control mice. Lr05V, Lr05NV and Lp06V treatments were the most effective to
induce the early recovery of bone marrow (BM) tissue architecture, leukocytes, myeloid,
pool mitotic and post-mitotic, peroxidase positive, and Gr-1Low/High cells in BM. We
selected the CRL1505 strain for being the one capable of maintaining its myelopoiesis-
enhancing properties in its non-viable form. Although the CRL1505 treatments do not
modify the Cy ability to induce apoptosis, both increased the incorporation of BrdU in BM
cells. Consequently, Lr05NV and Lr05V treatments were able to promote early recovery of
LSK cells (Lin-Sca-1+c-Kit+ cells), multipotent progenitors (Lin-Sca-1+c-Kit+CD34+ cells),
and myeloid cells (Gr-1+Ly6G+Ly6C- cells) with respect to the untreated Cy control. In
addition, these treatments were able to increase the frequency of IL17A-producing innate
lymphoid cells in the intestinal lamina propria (IL-17A+RORgt+CD4-NKp46+ cells) after Cy
injection. These results were correlated with an increase in the IL-17A serum levels, a GM-
CSF high expression and a CXCL12 lower expression in BM. Therefore, both Lr05V and
Lr05NV treatments are able to activate beneficially the IL-17A/GM-CSF axis and
accelerate the recovery of Cy-induced immunosuppression by increasing BM myeloid
precursors. We demonstrated for the first time the beneficial effect of CRL1505 strain onorg April 2021 | Volume 12 | Article 6470491
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and safe resource for reducing chemotherapy-induced leukopenia. The results are a
starting point for future research and open up broad prospects for future applications of
the immunobiotics.Keywords: myelopoiesis, lactobacilli, immunobiotic, cyclophosphamide, non-viable LactobacillusINTRODUCTION
Myelosuppression is the major dose-limiting toxicity of systemic
cancer chemotherapy (1). Cyclophosphamide (Cy) is a widely used
alkylating anti-cancer drug with a high therapeutic index and broad
spectrum of antitumor activity (2, 3). Moreover, Cy induces dose-
limiting suppression of proliferating hematopoietic progenitor cells
and results in a marked neutropenia, but dose reductions could
affect treatment efficacy (4, 5). At present, hematological rescue
techniques, such as hematopoietic progenitor transplantation or
administration of recombinant granulocyte colony-stimulating
factor are applied to reduce the Cy-induced neutropenia (6–8).
However, these treatments include new adverse effects,
hospitalization fees, nosocomial pathogens exposition and pour
life quality. Therefore, it is important to have safe agents capable of
reducing myelosuppression and improving morbidity in patients
undergoing chemotherapy. In recent years, probiotic lactic acid
bacteria (LAB) has shown promising results in this regard.
Some immunomodulatory LAB can be a valuable tool to
accelerate recovery from myelopoiesis and improve resistance to
infections in immunosuppressed mice. We have previously shown
that Lactobacillus (L.) rhamnosus CRL1505 increased resistance
against infect ions in both immunocompetent and
immunocompromised mice (9–11). The strain CRL1505 is able to
accelerate the recovery of ontogeny B in bone marrow (BM) and
spleen (10–13); potentiate basal myelopoiesis and improve
emergency myelopoiet ic response in malnutr i t ion-
immunosuppressed hosts (13, 14). In addition, the preventive
admin i s t ra t ion of L . p lan tarum CRL1506 to Cy-
immunosuppressed mice increases resistance to opportunistic
pathogens, as it improves BM myeloid cells and the innate
immune response (15). The protective effects of immunobiotics
depend on the administration way used, being the oral way themost
efficient to potentiate myelopoiesis (16). However, the consumption
of live microorganisms by immunosuppressed patients may
represent a potential risk to their health. While the viability of the
LAB is an important factor to achieve optimal beneficial effects, it is
possible to stimulate immunity using non-viable LAB (17, 18).
The aim of this work is to study the ability of viable and non-
viable immunobiotics to minimize myelosuppressive and
immunosuppressive effects derived from chemotherapy.MATERIALS AND METHODS
Probiotic Lactic Acid Bacteria
L. rhamnosus CRL1505 and L. plantarum CRL1506 were selected
because of their immunomodulatory capacity (9, 10, 16). Theseorg 2strains were obtained from the CERELA culture collection
(Chacabuco 145, San Miguel de Tucumán, Argentina). The
lyophilized strains were rehydrated in a medium containing
peptone (1.5%), tryptone (1%), meat extract (0.5%) in distilled
water at pH 7. The microorganims were cultured for 12 h at 37°C
(final log phase) in Man-Rogosa-Sharpe broth (MRS, Oxoid).
The bacteria were harvested by centrifugation at 3000 g for
10 min, washed three times with sterile 0.01 mol/l phosphate
buffer saline (PBS), pH 7.2, and resuspended in sterile on PBS.
Non-viable lactobacilli were obtained by exposition to ultraviolet
radiation for 2 hours. The absence of bacterial growth was
confirmed using MRS agar plates. Viable and non-viable LAB
were harvested by centrifugation and washed with sterile 0.01
mol/l PBS, pH 7.2. Finally, bacteria were suspended in 10% non-
fat milk to be administered to mice.
Murine Model of Chemotherapy Induced
Myelosuppression
6-week-old Swiss-albino male mice were obtained from
CERELA. The myelosuppression was induced in all animals by
intraperitoneal injection of Cy (150 mg/kg) on day 0 as
previously described (15). During the 10-day study,
immunosuppressed mice were housed in plastic cages, were
kept in controlled environmental conditions with light dark
cycles of 12 h, and were fed balanced conventional diet and
sterilized water ad libitium. Researchers and special staff trained
in animal handling and care were in charge of animal welfare,
and monitored animal health and behavior twice a day. We
strived to minimize the number of animals and their suffering.
During the experimental period no signs of discomfort or pain
were observed in the animals. Also, no deaths were reported
before the mice reached end points. The CERELA Institutional
Animal Care and Use Committee prospectively approved this
study under the protocol CRL-BIOT-BCE-2013/2A, and all
experiment comply with the current laws of Argentina and all
international organizations for the use of experimental animals.
Treatment of Cy-Induced
Myelosuppressive Mice With LAB
Different groups of mice were fed with 108 cells/mouse/day of
viable or non-viable L. rhamnosus CRL1505 (Lr05V+Cy or
Lr05NV+Cy groups) or L. plantarum CRL1506 (Lp06V+Cy or
Lp06NV+Cy groups) for 5 consecutive days before injection of
Cy. These doses were previously selected as optimal for effects on
the immune system (9). A control group (Cy group) consisted of
animals that did not receive immunobiotic treatment (Figure 1).
Six animals per group each time were used in the experiments.
Determinations described below were performed on day 0April 2021 | Volume 12 | Article 647049
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administration for 10 days.
Histological Studies
The femoral bone from the different experimental groups was
removed and immediately immersed in 4% paraformaldehyde,
decalcified in 50% formic acid and 15% sodium citrate, and
processed by standard histological techniques (paraffin-
embedding) (13). 5 um sections from femurs were stained with
Hematoxylin-Eosin.
Total and Differential Leukocyte Count in
Blood and BM
Blood samples were obtained from ketamine-xylazine-
anesthetized animals by cardiac puncture in heparinized tubes.
BM samples were obtained by flushing the femoral cavity with
phosphate-buffered saline (PBS). A Neubauer counting chamber
was used to count the blood and BM total number of leukocytes.
The differential cell counts were carried out with smears stained
with May Grünwald Giemsa under a light microscope (100x),
and absolute numbers were calculated as described
previously (15).
Blood and BM Myeloperoxidase Activity
The myeloperoxidase (MPO) activity was used as a marker of
myeloid cells in BM, and to evaluate functionality of myeloid
cells in blood. Washburn test was used to measure the MPO
activity. The results were expressed as percentages of peroxidase
positive (Px+) cells (12).
Isolation of BM Cells and Flow Cytometry
Single cell suspension from BM was prepared as previously
described (16). 1 x 106 cells were blocked with anti-mouse
CD32/CD16 monoclonal antibody (BD Biosciences) and then
stained with fluorescein isothiocyanate (FITC)-conjugated anti–
mouse Ly6G antibody (clone 1A8, BD Biosciences);Frontiers in Immunology | www.frontiersin.org 3phycoerythrin (PE)-conjugated anti–mouse Gr-1 antibody
(clone RB6-8C5, BD Biosciences), biotinylated-conjugated anti-
mouse Ly6C antibody (clone AL-21, DB Biosciences); FICT-
conjugated anti-mouse CD34 antibody (clone RAM34, BD
Biosciences); biotinylated-conjugated anti-mouse Ly 6A/E
antibody (Sca-1, clone D7, BD Biosciences); PE-conjugated
anti-mouse CD117 antibody (C-kit , clone 2B8, DB
Biosciences); FITC-conjugated anti-mouse TER-119/Erythroid
cells antibody (clone Terr-119, BD Biosciences); and
allophycocyanin (APC) mouse lineage antibody cocktail (clone
145-2C11). Following incubation with biotinylated primary
antibodies, the labeling was revealed using streptavidin-PercP.
The cells were acquired on a FASCalibur™ flow cytometer (BD
Biosciences) and data were analyzed with FlowJo software
(Tree Star).
Apoptosis Assay
The BM cells of different experimental groups were harvested
12 h after Cy administration. Apoptosis of 1 x 106 cells was
determined with a FITC Annexin V Apoptosis Detection Kit I
(BD Pharmingen). The suspension was analyzed by using
FASCalibur™ flow cytometer (BD Biosciences) and data were
analyzed with FlowJo software (Tree Star).
Isolation of Lamina Propria Lymphocytes
and Flow Cytometry
Lamina propria cells were obtained using the methodology of
Deshmukh et al. (19) with modifications. Proximal ilea sections
were removed from the different experimental groups on days 0,
3, 7 and 10 post-Cy, and minced into small pieces. Then, the cut
tissues were incubated for 60 min with 300 U of Type I
collagenase (Sigma-Aldrich) in 2 ml of RPMI 1640 medium
(Sigma-Aldrich). The collagenase-treated minced tissues were
gently grated into a plastic dish to obtain a single cell suspension,
filtered and depleted of erythrocytes by hypotonic lysis (Tris-
ammonium chloride, BD PharMingen). The cells were washedFIGURE 1 | Schematic representation of the feeding protocols used in this study. Treatment of mice by feeding with viable or non-viable L. rhamnosus CRL1505
(Lr05V+Cy or Lr05NV+Cy groups) or L. plantarum CRL1506 (Lp06V+Cy or Lp06NV+Cy groups) for 5 consecutive days before injection of Cy. A control group (Cy
group) were mice without probiotic treatment. Determinations were performed on day 0 (before Cy administration) and in different times after Cy administration for 10
days. The black down arrows indicate the sampling day. In the experiments 6 animals were used per group for each time point.April 2021 | Volume 12 | Article 647049
Gramajo et al. Lactobacillus Strains Improve the Myelopoiesisand resuspended in RPMI supplemented with 4% FCS. 1 x 106
cells were blocked with anti-mouse CD32/CD16 monoclonal
antibody (BD Biosciences) and then stained with fluorescein
isothiocyanate (FITC)-conjugated anti-mouse CD335 antibody
(NKp46) and biotinylated-conjugated anti-mouse CD4 antibody
(BD Biosciences). Following incubation with biotinylated
primary antibody, the labeling was revealed using streptavidin-
PercP. For intracellular staining, the cells were fixed and
permeabilized using Cytofix/Cytoperm and Permeabilization
buffers (BD Biosciences) according to manufacturer
instructions. Then, the cells were intracellularly stained
with phycoerythrin (PE)-conjugated anti–mouse IL17A
antibody and Alexa-conjugated anti–mouse RORg antibody
(BD Biosciences). The data were collected with a FASCalibur™
flow cytometer (BD Biosciences) and analyzed with FlowJo
software (Tree Star).
BrdU-Incorporation
The APC-BrdU-Flow-Kit (BD Pharmingen) was used for the
analysis of BrdU-incorporation into bone marrow cells. After a
single intraperitoneal injection of BrdU solution (1 mg/6g of
body weight), BrdU was also administered at 1 mg/ml with
drinking water for 3 days.
Quantitative Expression Analysis by Real-
Time PCR
We performed three-step real-time quantitative PCR to
characterize the expression of CXCL12, GM-CSF, IL-1b, IL-3
and SCF mRNAs in BM. TRIzol reagent (Invitrogen) was used
to isolate the total RNA from each sample. All RNA samples
were quantified using Qubit® RNA HS Assay Kit (Invitrogen)
with the Qubit® Fluorometer. All cDNAs were synthesized
using a reverse transcription (RT) kit (SuperScript III First-
Strand Synthesis SuperMix, Invitrogen) according to the
manufacturer’s recommendations. Real Time qPCR was
performed on an iQ5 Real-Time PCR Detection System
(BioRad) with the IQTM SYBR®supermix (Bio-Rad) in 96-well
plates. The following primers were used: CXCL12 (sense: 5’-GTC
CTC TTG CTG TCC AGC TC-3’; antisense: 5’- TAA TTT CGG
GTC AAT GCA CA-3’); GM-CSF (sense: 5’-CAT CAA AGA
AGC CCT GAA CC-3’; antisense: 5’-TGC ATT CAA AGG GGA
TAT CAG-3’); IL-1b (sense: 5’-GAC CTT CCA GGA TGA GGA
CA-3’; antisense: 5’-AGG CCA CAG GTA TTT TGT CG-3’); IL-
3 (sense: 5’-TAG GGA AGC TCC CAG AAC CT-3’; antisense:
5’-TTA GGA GAG ACG GAG CCA GA-3’); SCF (sense: 59-
CGG GAA TCC TGT GAC TGA TAA-39; antisense: 59-GGC
CTC TTC GGA GAT TCT TT-39). PCR was performed with 1
mL of cDNA or water in the non-template controls, 4 mL of
primer mix (0.3 mM of each primer), 5 mL of RNase-free water
and 10 mL of IQTM SYBR® Green Supermix (BioRad). The PCR
cycles consisted in: 95°C for 5 min, 40 cycles of 95°C for 30 sec,
55°C for 20 sec, 72°C for 30 sec and 95°C for 1 min. A melting
curve analysis was performed immediately at the end of
each experiment at a linear temperature transition rate of
0.5°C/sec from 55 to 95°C to determine the specificity of the
amplification. The relative mRNA expression (as fold change)Frontiers in Immunology | www.frontiersin.org 4was determined relative to a positive control after normalizing to
a housekeeping gene (b-actin) using the 2−DDCT or Livak
method (20).
Serum IL-17 Measurement
The concentration of IL-17 was measured in serum samples from
the different experimental groups on days 0, 3, 7 and 10 post-Cy
by using commercially available cytometric bead array (CBA)
technique, following the manufacturer’s recommendations
(Mouse Flex Set, BD Bioscience, San Diego, CA, USA). Briefly,
serum samples were diluted 1:2 with the assay diluent. The
lyophilised standard was reconstituted in an assay diluent to have
a standard curve. The capture beads were added to each tube
(standard and samples). After incubation for 1 h at room
temperature, PE detection reagent was added to each tube,
followed by gentle mixing and incubation for 2 h at room
temperature. After this, a wash buffer was added to each test
tube before centrifuging. Finally, the supernatants were
discarded and the wash buffer was added to resuspend the
beads. Standards and samples were acquired on the BD
FACSCalibur™ flow cytometer. The data were analyzed with
the FCAP Array™ software (BD, Bioscience). The results were
expressed in pg/mL using the standard curve performed with
different concentrations of the cytokine.
Statistical Analysis
GraphPad Prism software version 6.0 was used to perform
statistical analysis. The results of three independent
experiments were expressed as the mean ± SD. 2-way ANOVA
was applied to normal distribution of data. The differences
between the two groups were studied by comparing the means
in pairs by Tukey test. Differences were considered significant
at P<0.05.RESULTS
Effect of Lactobacilli on BM Tissue
Damage Induced by Cy
It is known that Cy administration induced noteworthy
alterations of BM histological characteristics (15). Thus, Cy-
treated mice showed hipocellularity with reduction of the
myeloid/erythroid ratio. In addition, sinusoidal alteration,
increased numbers of mature red blood cells and fat cells, and
loss of endostal epithelium were observed after Cy
administration (Figure 2A). However, the mice treated with
viable or non-viable lactobacilli showed fewer BM alterations
than the Cy group during the early days after Cy treatment.
Besides, recovery of tissue architecture was faster in the groups
treated with viable L. rhamnosus CRL1505 (Figure 2B).
Effect of Lactobacilli on BM and Blood
Leukocytes Counts Induced by Cy
Cy administration induced a severe decrease in the total BM cell
count at steady state, and the lowest number of cells was
registered on day 3 post-injection of Cy. From day 7, anApril 2021 | Volume 12 | Article 647049
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normal values throughout the period studied (Figure 3A).
Although on day 0 the studied groups presented similar
baseline counts, the mice supplemented with Lp06V showed
significantly higher values compared to the Cy group. In
addition, those treated with non-viable and viable L.
rhamnosus showed a less severe decrease in the total number
of cells on day 3 post-Cy compared to the Cy group, and an
earlier increase in the total number of cells observed on day 7
post-injection of Cy. Furthermore, the Lp06V+Cy and Lr05V
+Cy groups reached normal values on day 10 post-injection
(Figure 3A).
When morphologically recognizable elements were evaluated
on day 0, before Cy injection, we observed that the preventive
treatments with viable lactobacilli induced a significant increase
in myeloid cells and mitotic pool compared to control (Figures
3B, C). However, no significant differences were observed in the
post-mitotic pool cell count between the experimental groups
(Figure 3D). Cy injection produced a significant reduction in the
number of myeloid cells, mitotic and post-mitotic pools,
reaching the greatest deterioration on day 3 post-injection,
and the Cy group did not achieve normalization of theseFrontiers in Immunology | www.frontiersin.org 5parameters in the period studied (Figures 3B–D). Opposite to
this, the administration of viable lactobacilli induced a lower
decrease in myeloid cell counts, mitotic, and post-mitotic pool
cells on day 3 post-injection, and early recovery of these
populations compared to Cy group (Figures 3B–D). In
addition, the mice that received viable L. rhamnosus were able
to normalize these counts in the period studied. Interestingly, the
supplementation with non-viable L. rhamnosus showed a
significant increase in the number of myeloid cells on days 3
and 10, and mitotic pool cells on day 3 compared to Cy group
(Figures 3B, C).
The cytochemical study of the myeloid population in BM
supported the morphological study since Lp06V, Lr05NV
and Lr05V treatments induced an increase of the Px+ cell
count in BM with respect to the Cy group before and after
the Cy-administration (day 3) (Figure 3E). Furthermore, only
viable lactobacilli treatment could normalize this parameter from
day 7 post-Cy (Figure 3E).
Then, we studied the peripheral expression of Cy-induced
changes in BM and the effect of preventive treatments
(Figures 4A–D). Before Cy administration, leukocyte and Px+
cell counts showed no significant differences between the groupsA B
FIGURE 2 | Histological examination of bone marrow architecture. The femurs were removed from control mice (Cy group) (A), and mice treated with viable
Lactobacillus rhamnosus (Lr05V+Cy group) (B) on days 3, 7 and 10 post-Cy administration. The samples were fixed in paraformaldehyde, decalcified in formic acid
and sodium citrate, stained with hematoxylin and eosin and examined with a light microscope (400× and 1000× magnification). The results represent data from two
independent experiments. Six animals were used for each time point by groups. LEE, Loss of endostal epithelium; AEE, altered endostal epithelium; REE, recovered
endostal epithelium; RMER, reduced myeloid/erythroid ratio; NMER, normal myeloid/erythroid ratio; SA, sinusoidal alteration; NS, normal sinusoide.April 2021 | Volume 12 | Article 647049





FIGURE 3 | Bone marrow leukocytes. 6-week-old Swiss mice were fed with 108 cells/mouse/day of viable or non-viable Lactobacillus rhamnosus CRL1505 (Lr05V+
Cy or Lr05NV+Cy groups) or L. plantarum CRL1506 (Lp06V+Cy or Lp06NV+Cy groups) for 5 consecutive days before injection of Cy. The treated groups and the
untreated control mice (Cy group) received one dose of 150 mg/kg Cy intraperitoneally. Bone marrow leukocytes (A), myeloid cells (B), mitotic pool cells (C), post-
mitotic pool cells (D) and peroxidase + cells (E), counts were performed on day 0, before Cy administration, and days 3, 7 and 10 post-Cy administration. The
results come from two independent experiments. Six animals per group each time were used in the experiments. Results are expressed as mean ± SD. ***,**,*
Significant differences from the Cy group should be as follows (p<0.0001, p<0.001 or p< 0.05 respectively). Photomicrographs of May Grünwald Giemsa-stained
smears of bone marrow on day 3 post-Cy (Magnification X400) of normal control, and Cy, Lr05V+Cy and Lr05V+Cy groups (F).Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 6470496
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the Lr05V+Cy group showed a significantly higher count
compared to the Cy group (Figure 4B). Cy-administration
induced marked leukopenia and neutropenia in all
experimental groups, but with differences between them. Cy
group mice showed the lowest values leukocytes and Px+ cells
on day 3, with values 4 times lower than the basal value, reaching
normalization on day 10 post-injection. In addition, neutrophil
counts normalized from day 7 post-injection (Figures 3A–C).
The groups treated with L. rhamnosus and L. plantarum, viable
and non-viable, showed a less marked decrease in leukocyte
and Px+ cell values on day 3 post-Cy compared to the control.
No significant differences in the number of neutrophils were
observed between the supplemented groups compared to the Cy
group on day 3. The Lp06V+Cy and Lr05V+Cy groups were able
to normalize the leukocyte and Px+ cell counts from day 7 post-
injection, unlike the control, which normalized this parameter on
day 10 (Figures 4A, C). Despite the fact that all the
supplemented groups showed normal neutrophil values from
day 7 post-injection, the Lp06NV+Cy, Lp06V+Cy and Lr05V+Frontiers in Immunology | www.frontiersin.org 7Cy groups achieved a significantly higher count of this parameter
(Figure 4B).
Effect of Lactobacilli on Myeloid Cell
Maturation Impaired by Cy
Next, we assessed the effect of different treatments with both viable
and non-viable strains on the expression of Gr-1 cells (or a
myeloid cell marker) in BM and blood. Before Cy-injection,
Lr05V, Lr05NV and Lp06V treatments were able to increase the
numbers of Gr-1High and Gr-1Low cells in BM. Only the mice that
received the treatments with CRL1505 strain showed an increase
of blood Gr-1High cells. Additionally, blood Gr-1Low cells in
Lr06V+Cy and Lr05V+Cy mice were significantly higher than
the Cy group (Figure 5). Cyclophosphamide induced an abrupt
reduction of BM and blood Gr-1High and Gr-1Low cells on day 3
and 7 post-injection. However, Lr05NV+Cy and Lr05V+Cy mice
showed a number of BMGr-1High cells on day 3 and 7 higher than
the Cy group, as well as the number of BM Gr-1Low cells on day 3.
Only the viable CRL1506 strain had a similar effect on Gr-1Low
cells, comparable to the viable or non-viable CRL1505 strainA B
C D
FIGURE 4 | Blood leukocytes. 6-week-old Swiss mice were fed with 108 cells/mouse/day of viable or non-viable Lactobacillus rhamnosus CRL1505 (Lr05V+Cy or
Lr05NV+Cy groups) or L. plantarum CRL1506 (Lp06V+Cy or Lp06NV+Cy groups) for 5 consecutive days before injection of Cy. The treated groups and the untreated
control mice (Cy group) received one dose of 150 mg/kg Cy intraperitoneally. Blood leukocyte (A), neutrophils (B), and peroxidase positive (+) cells (C) counts were
performed on day 0, before Cy administration, and days 3, 7 and 10 post-Cy administration. The results come from two independent experiments. Six animals per group
each time were used in the experiments. Results are expressed as mean ± SD. ***,**,* Significant differences from the Cy group should be as follows (p<0.0001, p<0.005
or p<0.05 respectively). Photomicrographs of peroxidase+ neutrophils May Grünwald Giemsa-stained blood smears (Magnification X400) (D).April 2021 | Volume 12 | Article 647049
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maturation in BM with the viable and non-viable L.
rhamnosus CRL1505.
Lr05V y Lr05NV treatments were able to promoting the
steady-state myelopoiesis in BM before Cy-injection. On day 0,
viable and non-viable L. rhamnosus CRL1505 induced an
increase of the number of hematopoietic stem cells (LSK cells:
Lin-Sca-1+c-Kit+) (Figures 6A, G), multipotent progenitors
(MPP: Lin-Sca-1+c-Kit+CD34+ cells) (Figures 6B, G),
neutrophils and monocytes (Figures 6D, E, G) compared with
the Cy control in BM. Cyclophosphamide impaired myelopoiesisFrontiers in Immunology | www.frontiersin.org 8by decreasing the number of different parameters studied in
Figure 6 mainly observed on day 3 and 7. Preventive
administration of lactobacilli were equally effective in
promoting early recovery of myeloid cells after Cy
administration. Lr05V+Cy and Lr05NV+Cy mice showed
higher counts of LSK cells and erythroid precursors
(CD34+Gr-1-Terr119+ cells) on day 3 and 7, and MMPs on
day 3 compared with the Cy group (Figures 6A–C, G).
Regarding the mature cells studied, Lr05NV treatment induced
an increase in neutrophils from day 3 post-Cy, while Lr05V from
day 7 post-Cy (Figure 6D). Lr05NV and Lr05V mice showedA B
C D
E F
FIGURE 5 | Gr-1 expression in bone marrow and blood by flow cytometry. 6-week-old Swiss mice were fed with 108 cells/mouse/day of viable or non-viable
Lactobacillus rhamnosus CRL1505 (Lr05V+Cy or Lr05NV+Cy groups) or L. plantarum CRL1506 (Lp06V+Cy or Lp06NV+Cy groups) for 5 consecutive days before
injection of Cy. The treated groups and the untreated control mice (Cy group) received one dose of 150 mg/kg Cy intraperitoneally. Bone marrow Gr-1High cells (A),
and Gr-1Low cells (B), blood Gr-1High cells (C), and Gr-1Low cells (D) were performed on day 0, before Cy administration, and days 3, 7 and 10 post-Cy
administration. The results come from two independent experiments. Six animals per group each time were used in the experiments. Results are expressed as
mean ± SD. ***,**,* Significant differences from the Cy group should be as follows (p<0.0001, p<0.002 or p< 0.02 respectively). Gating strategy to study Gr-1High and
Gr-1Low cells in bone marrow (E), and in blood (F).April 2021 | Volume 12 | Article 647049





FIGURE 6 | Myelopoietic precursors in bone marrow by flow cytometry. 6-week-old Swiss mice were fed with 108 cells/mouse/day of viable or non-viable
Lactobacillus rhamnosus CRL1505 (Lr05V+Cy or Lr05NV+Cy groups) for 5 consecutive days before injection of Cy. The treated groups and the untreated control
mice (Cy group) received one dose of 150 mg/kg Cy intraperitoneally. Bone marrow LSK cells (A), multipotent progenitors (B), erythroid precursors (C), neutrophils
(D), and monocytes (E) were performed on day 0, before Cy administration, and days 3, 7 and 10 post-Cy administration. The results come from two independent
experiments. Six animals per group each time were used in the experiments. Results are expressed as mean ± SD. ***,**,* Significant differences from the Cy group
should be as follows (p<0.0001, p<0.002 or p< 0.02 respectively). (F) FSC vs SSC plots belong to days 0, 3, 7 and 10 post-Cy administration in the left-to-right
columns, and to the Cy, Lr05V+Cy and Lr05NV+Cy groups in the top-to-bottom rows. (G) Gating strategy to study bone marrow hematopoietic stem cells (LSK)
and myeloid linage cells: erythroid precursors, neutrophils and monocytes.Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 6470499
Gramajo et al. Lactobacillus Strains Improve the Myelopoiesismonocyte numbers higher than the Cy group throughout the
post-Cy period studied (Figure 6E).
Effect of Lactobacilli on Hematopoietic
Growth Factors and Cytokines Expression
Impaired by Cy
Before Cy injection, both lactobacilli treatments significantly
upregulated the expression of SCF, IL-1 and CXCL12 in the BM
showing levels that were significantly higher than the Cy control,
while IL-3 and GM-CSF expressions were not different from the Cy
group (Figure 7). Cy-injection significantly increased the
expression of SCF, IL-1, IL-3, GM-CSF and CXCL12 in BM of
Cy group mice on day 3 (Figure 7). The expression of SCF, IL-1
and IL-3 in both Lr05NV+Cy and Lr05V+Cy mice was lower than
in the Cy control on day 3 post-Cy (Figures 7A–C). In addition,
Lr05NV+Cy mice showed a lower expression of GM-CSF, while
Lr05V treatment increased the expression of this hematopoietic
growth factor compared with the control (Figure 7D). Besides,
mRNA levels of CXCL12 were significantly lower than Cy control
mice in Lr05V+Cy group. However, the Lr05NV+Cy group
CXCL12 expression was similar to the Cy group (Figure 7E). It
is convenient to note that on day 3 the expression of the IL-1 and
IL-3 in both Lr05NV+Cy and Lr05V+Cymice was similar to the Cy
control mice on day 0. Similarly, GM-SFC expression in Lr05NV
+Cy and CXCL12 in Lr05V+Cy were not different from the Cy
group mice before Cy-injection.
Effect of Lactobacilli on Apoptosis and
Proliferation of BM Cells During the Cy
Treatment
Next, we studied whether the immunoenhancing effect of the viable
or non-viable L. rhamnosus was due to the inhibition of apoptosis
induced by Cy, or due to an increase in the proliferation of myeloid
precursors. Cyclophosphamide induced 60% apoptosis of BM cells
at 12 h post-injection (Figures 8A, B). The preventive treatments
with Lr05V and Lr05NV did not show significant differences in the
percentage of apoptotic cells compared to the Cy control. Therefore,
both treatments did not prevent apoptosis damage in BM cells
(Figure 8A).
Then, we evaluated the lactobacilli influence on the proliferation
of BM cells, through the incorporation of bromodeoxyuridine and
subsequent detection by flow cytometry. The preventive
administration with both viable and non-viable L. rhamnosus was
able to increase significantly the incorporation of BrdU within BM
cells with blastoid morphology compared with the Cy group
(Figures 8C, D). No significant differences were observed when
evaluating BrdU-incorporation in myeloid cells (Figure 8C).
Role of the Intestinal Mucosa in the
Immunopotentiating Effect of Myelopoiesis
Induced by CRL1505 Strain
Finally,we studywhether as a consequenceof the interactionofviable
or non-viable L. rhamnosus CRL 1505 with the intestinal mucosa,
there is an increase in serum IL-17.We observed that the preventive
treatments with Lr05NV and Lr05V induced serum IL-17A levels
significantly higher thanCy control beforeCy-injection and on day 3Frontiers in Immunology | www.frontiersin.org 10post-Cy (Figure 9A). In addition, Lr05NV+Cy and Lr05V+Cymice
showed a greater ability to increase the percentage of group 3 innate
lymphoid cells (ILC3s) (CD4+IL-17+RORgt+NK+ cells) in the
intestinal lamina propria, since on day 0 and 3 post-Cy presented a
percentage of ILC3s higher than the Cy group (Figures 9B, C).DISCUSSION
In the last years there has been a large increase in the number of
immunocompromised patients due to different causes. Among
them, secondary immunodeficiency by chemotherapeutic
treatments is one of the most common reasons of morbidity in
cancer patients. Cancer is one of the principal causes of death
around the world. In 2018, there were 18 million new cases and
9.6 million cancer-related deaths (21). As mentioned above,
chemotherapeutics such as Cy have a high cytotoxicity on
tumor cells. However, they also damage healthy tissues, this is
why chemotherapy has important side effects (2–4).
Many attempts are being made to find safe immunoenhancing
agents that reduce myelosuppression and enhance the immune
response. For example, some plant extracts are known for their
specific biological properties, which when administered to Cy-
immunosuppressed animals are able to increase the immune
response (22–24). Polysaccharides of different origins have also been
described as protectors against myelosuppression and
immunosuppression caused by Cy (25–28). There is currently a
growing consumption of scientifically supported functional foods
and health promoting dietary supplements (29). In this sense,
probiotics have gained special interest (30) However, there is little
literature of the probiotics effect on the recovery of the immune
response impaired by treatment with immunosuppressive drugs. In
this regard, it has been shown that a L. plantarum strain is capable of
st imulating the proli feration of splenocytes of Cy-
immunocompromised mice in response to lipopolysaccharide (31).
However, Matsumoto et al. (32) demonstrated that the
Bifidobacterium longum BB536 increases the resistance to sepsis
caused by Pseudomonas aeruginosa in mice treated with Cy.
Recently, other researchers demonstrated that both L. plantarum
HY7712 and L. casei HY7213 can accelerate the recovery from Cy-
immunosuppression, immunopotentiating NK cells and cytotoxic T
lymphocytes, and restoration of themacrophages phagocytic capacity
(5, 33). Leaving aside the research carried out by our group there is no
other information about the potential effect of the administration of
immunobioticsonBM,especially about the fact that theycanstimulate
the myelopoiesis or improve the immune-hematopoietic response in
Cy-immunosuppressed hosts. Among the strains studied in our
laboratory, we selected L. rhamnosus CRL1505 and L. plantarum
CRL1506 for their efficiency to increase the resistance against
infections in both immunocompetent and immunocompromised
mice (9, 11). It is important to note that we chose oral
administration of immunobiotics because it was more effective than
nasal priming to enhance basal myelopoiesis and improve the
emergency myelopoietic response in malnourished host (16).
The indisputable histological alterations of BM caused by Cy
were reversed faster when the mice received a preventive treatmentApril 2021 | Volume 12 | Article 647049
Gramajo et al. Lactobacillus Strains Improve the Myelopoiesiswith viable or non-viable lactobacilli, being the Lr05V+Cy group
which showed the most evident changes. The histological studies of
BM during chemotherapy are poorly reported in the literature.
However, similar results were only observed with preventive
treatment with L. casei CRL431 (15), or with natural compounds
derived from herbal plants, like Ginseng or Rhus verniciflua using
different models of immunocompromised hosts (34, 35). Moreover,Frontiers in Immunology | www.frontiersin.org 11our histological results were correlated with the cell total counts and
cell morphologically recognizable counts in both BM and blood.
The treatments with Lr05V, Lr05NV and Lp06V were the most
effective to induce the early recovery of leukocytes, myeloid cells,
pool mitotic and post-mitotic cells and Px+ cells in BM. This
recovery was reflected in peripheral blood. At the same time, these




FIGURE 7 | Expression of hematopoietic growth factors and cytokines in bone marrow. 6-week-old Swiss mice were fed with 108 cells/mouse/day of viable or non-
viable Lactobacillus rhamnosus CRL1505 (Lr05V+Cy or Lr05NV+Cy groups) for 5 consecutive days before injection of Cy. The treated groups and the untreated
control mice (Cy group) received one dose of 150 mg/kg Cy intraperitoneally. Levels of mRNA of bone marrow CSF (A), IL-1b (B), IL-3 (C), GM-CSF (D), and
CXCL12 (E) were performed on day 0, before Cy administration, and day 3 post-Cy administration. The results come from two independent experiments. Six
animals per group each time were used in the experiments. Results are expressed as mean ± SD. **,* Significant differences from the Cy group should be as follows
(p<0.0001 or p<0.0002 respectively). # Significant difference from the Cy group on day 0 should be as follows (p<0.0001).April 2021 | Volume 12 | Article 647049
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these studies showing a myelopoiesis-enhancing effect during
chemotherapy, only showed morphologically recognizable cell
counts, perhaps because they were used in the follow-up of
patients during chemotherapy. However, we also demonstrated
that Lr05V, Lr05NV and Lp06V treatments were able to improve
the number of Gr-1Low cells, considered here as immature myeloid
cells, and Gr-1High cells as mature myeloid cells in BM and blood.
Taking in to account the results described up to this point, we
selected the strain CRL1505 for being the one capable of
maintaining its myelopoiesis-enhancing properties in its non-
viable form. Next, we deepened this study exploring the
precursors of the myeloid lineage in BM.
It is known that the hematopoietic stem cells (HSC) are
multipotent cells that reside in the BM and are characterized
by a small set of lineage markers as Lin-Sca-1+c-Kit+ (LSK cells)
(36). However, these phenotypically defined HSCs are
heterogeneous in their potential for differentiation into
progeny of multiple lineages and capacity for self-renewal (37,
38). A fraction of LSK cells gives rise to multipotent progenitors
(Lin-Sca-1+c-Kit+CD34+ MPPs), which in turn can generate
the megakaryocyte/erythrocyte lineage-restricted progenitorFrontiers in Immunology | www.frontiersin.org 12(Lin-Sca-1-c-Kit+FcgRII/III-CD34+ MEP) or the granulocyte/
macrophage lineage-restricted progenitor (Lin-Sca-1-c-Kit+FcgRII/
III+CD34+ GMP) (39). Our flow cytometry studies allowed to
characterize LSK cells, MPPs, erythroid precursors (CD34+Ter119+
cells), polymorphonuclear precursors (CD34+Gr-1+Ly6G+Ly6C-
cells) and monocyte precursors (CD34+Gr-1+Ly6G-Ly6C+ cells)
in Cy-immunocompromised mice. At this point, it is necessary
to emphasize that the effect of Lr05V and Lr05NV treatments
on myelopoiesis should be evaluated in the context of recovery
kinetics. Thus, on day 0 and on the first post-Cy days, the
preventive treatments mainly induced an increase of LSK cells and
MPPs, without significantly affecting the number of more mature
cells. At the end of the studied kinetics, the main effects of preventive
treatments are evidenced on immature polymorphonuclear cells and
monocytes. On the one hand, we can conclude that Lr05V and
Lr05NV treatments are able to stimulate myelopoiesis at steady-state.
At the same time these results were correlated with myelopoietic
growth factors. Before Cy-challenge, both treated groups showed a
high expression of CSF. On day 3, Lr05V+Cy group showed a high
expression of GM-CSF. In addition, both treated groups showed low
expression of CXCL12, an anchor sign of cells in BM. This would
favor the exit of mature myeloid elements from BM and explain theA C
B D
FIGURE 8 | Apoptosis and cellular proliferation studies. 6-week-old Swiss mice were fed with 108 cells/mouse/day of viable or non-viable L. rhamnosus CRL1505 (Lr05V
+Cy or Lr05NV+Cy groups) for 5 consecutive days before injection of Cy. The treated groups and the untreated control mice (Cy group) received one dose of 150 mg/kg Cy
intraperitoneally. (A) Apoptosis of bone marrow cells was determined by flow cytometry at 12 h post-Cy administration. (B) BrdU-incorporation into bone marrow cells was
performed on day 3 post-Cy administration. The results come from two independent experiments. Six animals per group each time were used in the experiments. Results
are expressed as mean ± SD. * Significant difference from the Cy group should be as follows (p<0.01). (C) The BrdU expression was analyzed by flow cytometry. (C) Gating
strategy to study bone marrow viable cells (Annexina V-,Propidium iodide-), cells in early apoptosis (Annexina V+,Propidium iodide-), and cells in later apoptosis (Annexina V+,
Propidium iodide+). (D) Gating strategy to study BrdU-incorporation in cells with blastoid morphology of bone marrow.April 2021 | Volume 12 | Article 647049
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obtained with strain CRL1505 in the recovery of myelopoiesis in
malnourished mice (16). On the other hand, these findings would be
framed under the paradigm of the hierarchical differentiation of
HSCs (39), opposing the idea of Sun et al. (40) and Busch et al. (41)
that steady-state hematopoiesis is sustained mainly by progenitors
rather than HSCs. While the consumption of live bacteria during
chemotherapy is not recommended due to a possible risk to the
patients’ health, our results support the treatment with the non-
viable CRL1505 strain since it maintains the myelopoiesis-
enhancement capacity of the viable strain. This strategy is hardly
considered in the bibliography. It is known that the heat-treatment of
bacteria disrupts the bacterial cell wall, inactivates protein and
releases the cellular contents (42). Because the principal target of
UV radiation is DNA, cell membranes of UV-killed cells retain not
only the capacity to transport specific molecules acting as a
permeability barrier, but also the capacity to maintain the electron
transport via protein and lipid carriers and a residual cytoplasmic
esterase activity (42). Therefore, in this work we used UV treatment
to obtain non-viable immunobiotics. In previous studies we
demonstrated that UV-killed L. rhamnosus CRL1505 was shown
to be equally effective as the viable strain in increasing resistance to S.
pneumoniae infection when administered nasally (18). This evidenceFrontiers in Immunology | www.frontiersin.org 13is essential when it comes to immunocompromised hosts with high
susceptibility to infections. However, the myeloenhancing effects of
viable bacteria are much more intense than that of the non-viable L.
rhamnosus CRL1505 when administered orally. We speculate that
despite giving the mice exactly the same dose, the viable bacteria can
resist gastrointestinal transit more successfully, interacting with the
intestinal mucosa immunity more effectively than the non-viable
bacteria. Surely, the UV-killed bacteria dose is lower at the intestinal
lumen than the viable strain. An oral delivery system would be
necessary to allow the non-viable bacteria to reach its action
site unchanged.
Next, our purpose was to know the possible mechanisms of the
myelopoiesis-enhancing effect of Lr05V and Lr05NV. We showed
that even though preventive treatments do not modify the ability of
Cy to induce apoptosis in BM cells, both increased the incorporation
of BrdU in vivo in BM cells. This increase of proliferative capacity of
BM cells allowed the early recovery of the proper balance between
apoptosis andcell proliferation improving thehomeostatic condition
of HSCs in BM (43). Finally, another aspect considered was the
increasingly relevant role of intestinalmicrobiota in themaintenance
of hematopoiesis. It was demonstrated that the intestinal microbiota
is necessary to maintain systemic neutrophils in the circulation,
CD4+ T cells in the spleen, and HSCs in BM during steady-stateA
C
B
FIGURE 9 | Serum Il-17A and group 3 innate lymphoid cells in the intestinal lamina propria. 6-week-old Swiss mice were fed with 108 cells/mouse/day of viable or
non-viable Lactobacillus rhamnosus CRL1505 (Lr05V+Cy or Lr05NV+Cy groups) for 5 consecutive days before injection of Cy. The treated groups and the untreated
control mice (Cy group) received one dose of 150 mg/kg Cy intraperitoneally. Serum IL-17A level (A) and percentage of group 3 innate lymphoid cells in the intestinal
lamina propria (B) were performed on day 0, before Cy administration, and days 3, 7 and 10 post-Cy administration. The results come from two independent
experiments. Six animals per group each time were used in the experiments. Results are expressed as mean ± SD. **,* Significant differences from the Cy group
should be as follows (p<0.002 or p<0.05 respectively). (C) Gating strategy to study CD4+IL-17+RORgt+NK+ cells in the intestinal lamina propria.April 2021 | Volume 12 | Article 647049
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microorganisms can control the immune response at distant sites
such as BM are not fully understood. It has been shown that the IL-
23/IL-17/G-CSF axis participates in the regulation of myelopoiesis,
and the neutrophil homeostasis in basal conditions depends on G-
CSF, which is regulated through receptors of pattern recognition,
linking the Toll-like receptor (TLR) with granulopoiesis (44).
Microbiota derived components, such as LPS through TLR4/
MyD88 signaling, induced intestinal IL-17 production and
increased G-CSF plasma levels leading to granulocytosis (19). Here
we demonstrate that viable and non-viable L. rhamnosus CRL1505
are able to increase the frequency of IL17A-producing innate
lymphoid cells in the lamina propria of the small intestine (IL-
17A+RORgt+CD4-NKp46+) after injection of Cy. These results were
correlatedwith an increase in serum IL-17A levels. At the same time,
at 3 days post-Cy, Lr05V treatment induced a high expression of
GM-CSF and a lower expression ofCXCL12 inBM, compared to the
Cy group. Therefore, CRL1505 strain can beneficially activate the IL-
17A/GM-CSF axis and accelerate recovery from Cy-induced
immunosuppression by increasing the number of myeloid
progenitors in BM.
We venture to propose that the use of myeloenhancing
treatments with L. rhamnosus CRL1505 could reduce neutropenia
without affecting the success of chemotherapeutic treatments, even
regardless of the type of chemotherapeutic drug or tumor process.
On the one hand, this is based on the fact that the immunobiotic
CRL1505 treatments reinforce the physiological effects exerted by
the intestinal microbiota by stimulating myelopoiesis as noted
above. Furthermore, it is not ruled out that, when evaluating the
effects of this strain in the context of a tumor process, it may have
some anti-tumor effect per se, as has already been demonstrated for
other immunobiotic LAB strains (47). On the other hand, the use of
filgastrim is a common salvage therapy in different types of cancer.
However, the role of filgrastim during acute myeloid leukemia
(AML) induction therapy remains controversial (48). Patients
diagnosed with AML who received filgastrim showed no
significant difference regarding overall survival or progression-free
survival compared with AML patients not treated with this drug.
Furthermore, Abboud et al. (49) demonstrated that rG-CSF and
selinexor can be combined safely in patients with relapsed or
refractory acute myeloid leukemia. Moreouver, new studies using
immunobiotic treatments in experimental cancer models could
strengthen our results. The results shown here represent the
starting point of a young line of research. We have an optimistic
look at the possible application of these immunobiotics in patients
undergoing chemotherapy, because of previous studies that
demonstrated the ability to stimulate respiratory immunity in
experimental animals and later humans (50).
In conclusion, we demonstrated for the first time the beneficial
effect of L. rhamnosus CRL1505, an immunobiotic strain, on
myelopoiesis affected by a drug used in chemotherapeutic
treatments. Furthermore, we showed that although the viability of
the LAB is an important factor to achieve an optimal effect, the
administration of non-viable L. rhamnosus CRL1505 also induced
early recovery from steady-state myelopoiesis in Cy-
immunosuppressed hosts. The results of this work provide theFrontiers in Immunology | www.frontiersin.org 14scientific basis to propose non-viable L. rhamnosus CRL1505 as a
new bioactive agent that enhances myelopoiesis. Its future
application as a good and safe nutritional supplement in
immunosuppressed pacients by chemotherapeutic drugs would
make it possible to reduce the time required for the recovery of
myelopoietic capacity and consequently the recovery of immunity.
This would have an important impact on the management of these
patients, since it would allow an optimal implementation of
conventional therapy and improve their life quality. The results are
a starting point for future research and open up broad prospects for
future applications of the immunobiotics.DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in
the article/supplementary material. Further inquiries can be
directed to the corresponding author.ETHICS STATEMENT
The animal study was reviewed and approved by this study was
carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
Guidelines for Animal Experimentation of CERELA. The
CERELA Institutional Animal Care and Use Committee
prospectively approved this research under the protocol CRL-
BIOT-BCE-2013/2A. Researchers and special staff trained in
animal handling and care were in charge of animal welfare,
and monitored animal health and behavior twice a day. We
strived to minimize the number of animals and their suffering.
During the experimental period no signs of discomfort or pain
were observed in the animals. Also, no deaths were reported
before the mice reached end points.AUTHOR CONTRIBUTIONS
SS and SA designed the study. AG, LS, EH, and SS did the
experiments. SS, SA, and EH provided financial support. SS, SA,
AG, and FG contributed to data analysis and results
interpretation. SS and SA wrote the manuscript. All authors
contributed to the article and approved the submitted version.FUNDING
This study was supported by grants of the Agencia Nacional de
Ciencia y Técnica (PICT-2018-1093 and PICT-2018-3264) and
CONICET (PIP272 and PIP531).ACKNOWLEDGMENTS
We thank Dr. G. Marranzino for her assistance with RNA isolation.April 2021 | Volume 12 | Article 647049
Gramajo et al. Lactobacillus Strains Improve the MyelopoiesisREFERENCES
1. Lyman GH. Risks and consequences of chemotherapy induced neutropenia.
Clin Cornerstone (2006) 8:S12–8. doi: 10.1016/s1098-3597(06)80054-2
2. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden
anniversary. Nat Rev Oncol (2009) 6:638–47. doi: 10.1038/nrclinonc.2009.146
3. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L.
Immunomodulatory effects of cyclophosphamide and implementations for
vaccine design. Semin Immunopathol (2011) 33:369–83. doi: 10.1007/s00281-
011-0245-0
4. Vogels MT, Hermsen CC, Huys HL, Eling WM, van der Meer JW. Roles of
tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating
factor, platelet-activating factor, and arachidonic acid metabolites in
interleukin-1-induced resistance to infection in neutropenic mice. Infect
Immun (1994) 62:2065–70. doi: 10.1128/IAI.62.5.2065-2070.1994
5. Jang SE, Joh EH, Lee HY, Ahn YT, Lee JH, Huh CS, et al. Lactobacillus
p lan tarum HY7712 ame l io ra t e s cyc lophosphamide- induced
immunosuppression in mice. J Microbiol Biotechnol (2013a) 23:414–21.
doi: 10.4014/jmb.1210.10010
6. Altwairgi AK, Hopman WM, Mates M. Real-world impact of granulocyte-
colony stimulating factor on febrile neutropenia. Curr Oncol (2013) 20:e171–
9. doi: 10.3747/co.20.1306
7. Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating
factors for febrile neutropenia during cancer therapy. N Engl J Med (2013)
368:1131–9. doi: 10.1056/NEJMct1210890
8. Lee KH, Kim JY, Lee MH, Han HS, Lim JH, Park KU, et al. A randomized,
multicenter, phase II/III study to determine the optimal dose and to evaluate
the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced
neutropenia compared to pegfilgrastim in breast cancer patients: KCSG
PC10-09. Support Care Cancer (2016) 24:1709–17. doi: 10.1007/s00520-
015-2963-7
9. Salva S, Villena J, Alvarez S. Immunomodulatory activity of Lactobacillus
rhamnosus strains isolated from goat milk: impact on intestinal and
respiratory infections. Inter J Food Microbiol (2010) 141:82–9. doi: 10.1016/
j.ijfoodmicro.2010.03.013
10. Salva S, Nuñez M, Villena J, Ramón A, Font G, Alvarez S. Development of a
probiotic fermented goat milk containing Lactobacillus rhamnosus. In vivo
study of health benefits. J Sci Food Agricul (2011) 91(13):2355–62.
doi: 10.1002/jsfa.4467
11. Barbieri N, Villena J, Herrera M, Salva S, Alvarez S. Nasally administered
Lactobacillus rhamnosus accelerate the recovery of humoral immunity in B
lymphocyte-deficient malnourished mice. J Nutr (2013) 143:227–35.
doi: 10.3945/jn.112.165811
12. Salva S, Villena J, Racedo S, Alvarez S, Agüero G. Lactobacillus casei addition
to a repletion diet induced early normalization of cytokine profiles during
pneumococcal infection in malnourished mice. Food Agricul Immunol (2008)
19:195–211. doi: 10.1080/09540100802247243
13. Salva S, Merino MC, Agüero G, Gruppi A, Alvarez S. Dietary supplementation
with probiotics improves hematopoiesis in malnourished mice. PLoS One
(2012) 7:e31171. doi: 10.1371/journal.pone.0031171
14. Herrera M, Salva S, Villena J, Barbieri N, Alvarez S. Lactobacillus rhamnosus
CRL1505 enhances systemic and respiratory innate immune response in
immunocompromised malnourished mice. J Funct Foods (2013) 143:227–
35. doi: 10.3920/BM2016.0152
15. Salva S, Marranzino G, Villena J, Agüero G, Alvarez S. Probiotic Lactobacillus
strains protect against myelosuppression and immunosuppression in
cyclophosphamide-treated mice. Int Immunopharmacol (2014) 22:209–21.
doi: 10.1016/j.intimp.2014.06.017
16. Herrera M, Salva S, Villena J, Barbieri N, Marranzino G, Alvarez S. Dietary
supplementation with lactobacilli improves emergency granulopoiesis in
protein-malnourished mice and enhances respiratory innate immune
response. PLoS One (2014) 9:e90227. doi: 10.1371/journal.pone.0090227
17. Villena J, Barbieri NP, Salva S, Herrera HM, Alvarez S. Enhanced immune
response to pneumococcal infection in malnourished mice nasally treated
with heat-killed Lactobacillus casei. Microbiol Immunol (2009) 53:636–46.
doi: 10.1111/j.1348-0421.2009.00171.x
18. Kolling Y, Salva S, Villena J, Marranzino G, Alvarez S. Non-viable
immunobiotic Lactobacillus rhamnosus CRL1505 and its peptidoglycanFrontiers in Immunology | www.frontiersin.org 15improve systemic and respiratory innate immune response during recovery
of immunocompromised-malnourished mice. Inter Immunopharmacol
(2015) 25:474–84. doi: 10.1016/j.intimp.2015.02.006
19. Deshmukh HS, Liu Y, Menkiti OR, Mei J, Dai N, O’Leary CE, et al. The
microbiota regulates neutrophil homeostasis and host resistance to
Escherichia coli K1 sepsis in neonatal mice. Nat Med (2014) 20:524–30.
doi: 10.1038/nm.3542
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (2001)
25:402–8. doi: 10.1006/meth.2001.1262
21. Wild CP, Weiderpass E, Stewart BW.Data from: World Cancer Report: Cancer
Research for Cancer Prevention. Lyon, France: International Agency for
Research on Cancer. France: Licence: CC BY-NC-ND 3.0 IGO (2020).
Available at: http://publications.iarc.fr/586.
22. Fan Y, Lu Y, Wang D, Liu J, Song X, Zhang W, et al. Effect of epimedium
polysaccharide-propolis flavone immunopotentiator on immunosuppression
induced by cyclophosphamide in chickens. Cell Immunol (2013) 281:37–43.
doi: 10.1016/j.cellimm.2013.01.008
23. Hussain A, Shadma W, Maksood A, Ansari SH. Protective effects of
Picrorhizakurroa on cyclophosphamide-induced immunosuppression in
mice. Pharmacognosy Res (2013) 5:30–5. doi: 10.4103/0974-8490.105646
24. Djafoua YM, Mouokeu RS, Tume C, Kamtchueng MO, Kuiate JR.
Immunomodulatory activity of methanol leaf extracts of Cameroonian
medicinal plants. J Complement Integr Med (2015) 12:267–75. doi: 10.1515/
jcim-2014-0023
25. Harnack U, Eckert K, Fichtner I, Pecher G. Comparison of the effect of orally
administered soluble beta-(1-3), (1-6)-D-glucan and of G-CSF on the recovery
of murine hematopoiesis. In Vivo (2010) 24:59–63.
26. Wang H, Wang M, Chen J, Tang Y, Dou J, Yu J, et al. A polysaccharide from
Strongylocentrotus nudus eggs protects against myelosuppression and
immunosuppress ion in cyc lophosphamide- trea ted mice . In t
Immunopharmacol (2011) 11:1946–53. doi: 10.1016/j.intimp.2011.06.006
27. Zhu XL, Liu JH, Li WD, Lin ZB. Promotion of myelopoiesis in
myelosuppressed mice by Ganoderma lucidum polysaccharides. Front
Pharmacol (2012) 3:20. doi: 10.3389/fphar.2012.00020
28. Chen X, Nie W, Fan S, Zhang J, Wang Y, Lu J, et al. A polysaccharide from
Sargassum fusi forme protects against immunosuppress ion in
cyclophosphamide-treated mice. Carbohydr Polym (2012) 90:1114–9.
doi: 10.1016/j.carbpol.2012.06.052
29. Wohlgemuth S, Loh G, Blaut M. Recent developments and perspectives in the
investigation of probiotic effects. Int J Med Microbiol (2010) 300:3–10.
doi: 10.1016/j.ijmm.2009.08.003
30. Abedin-Do A, Taherian-Esfahani Z, Ghafouri-Fard S, Ghafouri-Fard S,
Motevaseli E. Immunomodulatory effects of Lactobacillus strains: emphasis
on their effects on cancer cells. Immunotherapy (2015) 7:1307–29.
doi: 10.2217/imt.15.92
31. Bujalance C, Moreno E, Jimenez-Valera M, Ruiz-Bravo A. A probiotic strain
of Lactobacillus plantarum stimulates lymphocyte responses in
immunologically intact and immunocompromised mice. Int J Food
Microbiol (2007) 113:28–34. doi: 10.1016/j.ijfoodmicro.2006.07.014
32. Matsumoto T, Ishikawa H, Tateda K, Yaeshima T, Ishibashi N. Oral
administration of Bifidobacterium longum prevents gut-derived
Pseudomona aeruginosa sepsis in mice. J Appl Microbiol (2008) 104:672–80.
doi: 10.1111/j.1365-2672.2007.03593.x
33. Jang SE, Joh EH, Ahn YT, Huh CS, Han MJ, Kim DH. Lactobacillus casei
HY7213 ameliorates cyclophosphamide-induced immunosuppression in
mice by act ivat ing NK, cytotoxic T cel l s and macrophages .
Immunopharmacol Immunotoxicol (2013b) 35:396–402. doi: 10.3109/
08923973.2013.789055
34. Sun X, Zhao YN, Qian S, Gao RL, Yin LM, Wang LP, et al. Ginseng-derived
Panaxadiol Saponins promote hematopoiesis recovery in cyclophosphamide-
induced myelosuppressive mice: potential novel treatment of chemotherapy-
induced cytopenias. Chin J Integr Med (2018) 24:200–6. doi: 10.1007/s11655-
017-2754-8
35. Kim HS, Kim HG, Im HJ, Lee JS, Lee SB, Kim WY, et al. Antiemetic and
Myeloprotective Effects of Rhus verniciflua Stoke in a Cisplatin-Induced Rat
Model. Evid Based Complement Alternat Med (2017) 2017:9830342.
doi: 10.1155/2017/9830342April 2021 | Volume 12 | Article 647049
Gramajo et al. Lactobacillus Strains Improve the Myelopoiesis36. Morrison SJ, Weissman IL. The long-term repopulating subset of
hematopoietic stem cells is deterministic and isolatable by phenotype.
Immunity (1994) 1:661–73. doi: 10.1016/1074-7613(94)90037-x
37. Benz C, Copley MR, Kent DG, Wohrer S, Cortes A, Aghaeepour N, et al.
Hematopoietic stem cell subtypes expand differentially during development
and display distinct lymphopoietic programs. Cell Stem Cell (2012) 10:273–83.
doi: 10.1016/j.stem.2012.02.007
38. Chen JY, Miyanishi M, Wang SK, Yamazaki S, Sinha R, Kao KS, et al. Hoxb5
marks long-term haematopoietic stem cells and reveals a homogenous
perivascular niche. Nature (2016) 530:223–7. doi: 10.1038/nature16943
39. Cheng H, Zheng Z, Cheng T. New paradigms on hematopoietic stem cell
differentiation. Protein Cell (2020) 11:34–44. doi: 10.1007/s13238-019-0633-0
40. Sun J, Ramos A, Chapman B, Johnnidis JB, Le L, Ho YJ, et al. Clonal dynamics
of native haematopoiesis. Nature (2014) 514:322–7. doi: 10.1038/nature13824
41. Busch K, Klapproth K, Barile M, Flossdorf M, Holland-Letz T, Schlenner SM,
et al. Fundamental properties of unperturbed haematopoiesis from stem cells
in vivo. Nature (2015) 518:542–6. doi: 10.1038/nature14242
42. Villarino A, Bouvet OM, Regnault B, Martin-Delautre S, Grimont PAD.
Exploring the frontier between life and death in Escherichia coli: evaluation of
different viability markers in live and heat- or UV-killed cells. Res Microbiol
(2000) 151:755–68. doi: 10.1016/s0923-2508(00)01141-4
43. Sarvothaman S, Undi RB, Pasupuleti SR, Gutti U, Gutti RK. Apoptosis: role in
myeloid cell development. Blood Res (2015) 50:73–9. doi: 10.5045/br.2015.50.2.73
44. Bugl S, Wirths S, Radsak MP, Schild H, Stein P, André MC, et al. Steady-state
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